55 filings
Page 3 of 3
8-K
w38l5w
9 Nov 21
Inhibrx Reports Third Quarter 2021 Financial Results
4:37pm
8-K
od7zm
28 Oct 21
Departure of Directors or Certain Officers
8:50am
8-K
ua7y5qkfa56qfr
12 Oct 21
Regulation FD Disclosure
7:50am
8-K
l5glsdl0
3 Sep 21
Entry into a Material Definitive Agreement
4:33pm
8-K
zu5avm ftawjbc6sw
9 Aug 21
Inhibrx Reports Second Quarter 2021 Financial Results
4:12pm
8-K
071m1
21 Jun 21
Entry into a Material Definitive Agreement
4:05pm
8-K
wvw1su2i
9 Jun 21
Submission of Matters to a Vote of Security Holders
12:00am
8-K
2hkusjs
13 May 21
Inhibrx Reports First Quarter 2021 Financial Results
4:05pm
8-K
zuazs0fmnl0 su3m
12 Mar 21
Results of Operations and Financial Condition
8:55am
8-K
o7l254a is62v5jr
13 Jan 21
Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients
9:03am
8-K
vpz61k7xv4
5 Jan 21
Inhibrx Announces Phase 1 Dose Escalation Results of
12:00am
8-K
5gse9b8ujqj
13 Nov 20
Inhibrx Reports Financial Results for the Third Quarter 2020 and Announces Amended Loan Agreement with Oxford
4:13pm
8-K
xjrcji6v
12 Nov 20
Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients
6:07am
8-K
8phfqx6ga
11 Sep 20
Regulation FD Disclosure
4:24pm
8-K
a8yc888ocfmximxf
21 Aug 20
Unregistered Sales of Equity Securities
4:19pm